ARTICLE | Company News
Angiogen, Microbix deal
April 10, 2006 7:00 AM UTC
MBX received exclusive worldwide rights to commercialize Angiogen's Angiostatic Cocktail, which is in Phase I testing for cancer. The product contains urokinase and an undisclosed small molecule. MBX ...